Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
10.1186/s12885-015-1764-1
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/181427 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
id |
sg-nus-scholar.10635-181427 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-1814272024-04-25T02:38:08Z Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum Glynne-Jones, R Hava, N Goh, V Bosompem, S Bridgewater, J Chau, I Gaya, A Wasan, H Moran, B Melcher, L MacDonald, A Osborne, M Beare, S Jitlal, M Lopes, A Hall, M West, N Quirke, P Wong, W.-L Harrison, M and for the Bacchus investigato SURGERY bevacizumab fluorouracil folinic acid irinotecan oxaliplatin angiogenesis inhibitor antineoplastic agent bevacizumab advanced cancer Article cancer adjuvant therapy cancer combination chemotherapy cancer control cancer grading cancer prognosis cancer regression cancer size cancer staging colostomy computer assisted emission tomography continuous infusion controlled study disease free survival drug efficacy drug monitoring drug safety drug tolerability feasibility study follow up high risk patient histopathology human human tissue multicenter study multiple cycle treatment nuclear magnetic resonance imaging open study outcome assessment overall survival patient compliance phase 2 clinical trial preoperative treatment progression free survival prospective study randomized controlled trial rectum cancer rectum surgery total mesorectal excision treatment response abdominal surgery adjuvant chemotherapy aged clinical trial combination drug therapy female male neoadjuvant therapy prognosis Rectal Neoplasms treatment outcome Aged Angiogenesis Inhibitors Antineoplastic Agents Bevacizumab Chemotherapy, Adjuvant Digestive System Surgical Procedures Drug Therapy, Combination Female Humans Male Neoadjuvant Therapy Prognosis Prospective Studies Rectal Neoplasms Treatment Outcome 10.1186/s12885-015-1764-1 BMC Cancer 15 1 764 2020-10-27T10:53:29Z 2020-10-27T10:53:29Z 2015 Article Glynne-Jones, R, Hava, N, Goh, V, Bosompem, S, Bridgewater, J, Chau, I, Gaya, A, Wasan, H, Moran, B, Melcher, L, MacDonald, A, Osborne, M, Beare, S, Jitlal, M, Lopes, A, Hall, M, West, N, Quirke, P, Wong, W.-L, Harrison, M, and for the Bacchus investigato (2015). Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer 15 (1) : 764. ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-015-1764-1 14712407 https://scholarbank.nus.edu.sg/handle/10635/181427 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031 |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
topic |
bevacizumab fluorouracil folinic acid irinotecan oxaliplatin angiogenesis inhibitor antineoplastic agent bevacizumab advanced cancer Article cancer adjuvant therapy cancer combination chemotherapy cancer control cancer grading cancer prognosis cancer regression cancer size cancer staging colostomy computer assisted emission tomography continuous infusion controlled study disease free survival drug efficacy drug monitoring drug safety drug tolerability feasibility study follow up high risk patient histopathology human human tissue multicenter study multiple cycle treatment nuclear magnetic resonance imaging open study outcome assessment overall survival patient compliance phase 2 clinical trial preoperative treatment progression free survival prospective study randomized controlled trial rectum cancer rectum surgery total mesorectal excision treatment response abdominal surgery adjuvant chemotherapy aged clinical trial combination drug therapy female male neoadjuvant therapy prognosis Rectal Neoplasms treatment outcome Aged Angiogenesis Inhibitors Antineoplastic Agents Bevacizumab Chemotherapy, Adjuvant Digestive System Surgical Procedures Drug Therapy, Combination Female Humans Male Neoadjuvant Therapy Prognosis Prospective Studies Rectal Neoplasms Treatment Outcome |
spellingShingle |
bevacizumab fluorouracil folinic acid irinotecan oxaliplatin angiogenesis inhibitor antineoplastic agent bevacizumab advanced cancer Article cancer adjuvant therapy cancer combination chemotherapy cancer control cancer grading cancer prognosis cancer regression cancer size cancer staging colostomy computer assisted emission tomography continuous infusion controlled study disease free survival drug efficacy drug monitoring drug safety drug tolerability feasibility study follow up high risk patient histopathology human human tissue multicenter study multiple cycle treatment nuclear magnetic resonance imaging open study outcome assessment overall survival patient compliance phase 2 clinical trial preoperative treatment progression free survival prospective study randomized controlled trial rectum cancer rectum surgery total mesorectal excision treatment response abdominal surgery adjuvant chemotherapy aged clinical trial combination drug therapy female male neoadjuvant therapy prognosis Rectal Neoplasms treatment outcome Aged Angiogenesis Inhibitors Antineoplastic Agents Bevacizumab Chemotherapy, Adjuvant Digestive System Surgical Procedures Drug Therapy, Combination Female Humans Male Neoadjuvant Therapy Prognosis Prospective Studies Rectal Neoplasms Treatment Outcome Glynne-Jones, R Hava, N Goh, V Bosompem, S Bridgewater, J Chau, I Gaya, A Wasan, H Moran, B Melcher, L MacDonald, A Osborne, M Beare, S Jitlal, M Lopes, A Hall, M West, N Quirke, P Wong, W.-L Harrison, M and for the Bacchus investigato Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
description |
10.1186/s12885-015-1764-1 |
author2 |
SURGERY |
author_facet |
SURGERY Glynne-Jones, R Hava, N Goh, V Bosompem, S Bridgewater, J Chau, I Gaya, A Wasan, H Moran, B Melcher, L MacDonald, A Osborne, M Beare, S Jitlal, M Lopes, A Hall, M West, N Quirke, P Wong, W.-L Harrison, M and for the Bacchus investigato |
format |
Article |
author |
Glynne-Jones, R Hava, N Goh, V Bosompem, S Bridgewater, J Chau, I Gaya, A Wasan, H Moran, B Melcher, L MacDonald, A Osborne, M Beare, S Jitlal, M Lopes, A Hall, M West, N Quirke, P Wong, W.-L Harrison, M and for the Bacchus investigato |
author_sort |
Glynne-Jones, R |
title |
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
title_short |
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
title_full |
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
title_fullStr |
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
title_full_unstemmed |
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
title_sort |
bevacizumab and combination chemotherapy in rectal cancer until surgery (bacchus): a phase ii, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
publishDate |
2020 |
url |
https://scholarbank.nus.edu.sg/handle/10635/181427 |
_version_ |
1800914636922421248 |